Financials in CAD. Standardized financial statements.
A compact view of how RAMM Pharma Corp. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.36M | $4.34M | $5.07M | $3.90M | $4.12M | $5.44M | $5.61M | $8.35M |
| Revenue Growth? | -22.6% | -14.3% | +30.0% | -5.3% | -24.4% | -3.0% | -32.8% | 0.0% |
| Cost of Revenue? | $2.99M | $2.58M | $4.68M | $3.37M | $4.12M | $4.16M | $4.83M | $6.12M |
| Gross Profit? | $373,930 | $1.76M | $381,820 | $530,505 | -$7,641 | $1.28M | $783,186 | $2.22M |
| Gross Margin? | +11.1% | +40.6% | +7.5% | +13.6% | -0.2% | +23.6% | +14.0% | +26.7% |
| Operating Expenses? | $4.89M | $8.52M | $7.47M | $8.46M | $6.63M | $8.86M | $2.70M | $1.89M |
| Operating Income? | -$4.52M | -$6.76M | -$7.09M | -$7.93M | -$7.19M | -$7.58M | -$1.92M | $332,738 |
| EBITDA? | -$3.78M | -$15.23M | -$6.30M | -$19.91M | -$6.36M | -$6.91M | -$6.28M | -$252,642 |
| Income Before Tax | -$8.89M | -$16.49M | -$7.71M | -$20.95M | -$7.10M | -$7.43M | -$6.81M | -$678,933 |
| Income Tax Expense | $15,247 | $8,118 | $9,686 | $8,387 | $5,556 | $4,935 | $5,503 | $5,649 |
| Net Income? | -$8.91M | -$16.50M | -$7.72M | -$20.96M | -$7.11M | -$7.43M | -$6.82M | -$684,582 |
| EPS? | $-0.07 | $-0.14 | $-0.06 | $-0.17 | $-0.07 | $-0.07 | $-0.07 | $-0.01 |
| Diluted EPS? | $-0.07 | $-0.14 | $-0.06 | $-0.17 | $-0.07 | $-0.07 | $-0.07 | $-0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality